Effects of Omega-3-Polyunsaturated Fatty on Endothelial Function in Patients with Peripheral Arterial Disease: A Randomized, Placebo-Controlled, Double-Blind Trial.
As only limited evidence is available for potential benefits of omega-3 polyunsaturated fatty acids (n3-PUFA) supplementation in patients with peripheral arterial disease (PAD), we studied the effects of 4g n3-PUFA on endothelial function and inflammatory markers. Seventy patients with stable PAD classified as Rutherford stage 2 or 3 and good control of cardiovascular factors were randomized to receive either 4g n3-PUFA or placebo daily for 3 months in a double-blind fashion. Primary endpoint was endothelial function assessed by flow-mediated vasodilation (FMD). In addition, ankle-brachial index (ABI), maximum and pain-free walking distances were determined. Lipid parameters including omega-3 index reflecting n3-PUFA intake as well as pro-inflammatory, endothelial and platelet activation markers were measured over the same time interval. After 3 months of treatment with 4g n3-PUFA daily a significant improvement of FMD was observed compared to placebo (n3-PUFA, median (IQR): Δ 3.7% (-1.8, 7.1) vs. placebo: Δ -0.5% (-6.5, 3.0), P=0.01 between the groups). After a 3 months wash out period this benefit was not sustained (n3-PUFA, median (IQR): Δ 0.6% (-2.2, 5.6) vs. placebo: Δ -0.9% (-6.6, 6,7), P=0.20). In response to n3-PUFA, an improvement of lipid parameters with a pronounced increase of omega-3 index was seen. No changes were found for other parameters. In conclusion, in patients with PAD, 4g/d n3-PUFA improved endothelial function but not walking capacity. Thus, N3-PUFA supplementation might be a potential candidate for reduction of the excess CV risk in PAD patients, which needs testing in large scale trials. Trial registration: ClinicalTrials.gov NCT01367145.